Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
Completed · Phase 1 · NCT03950739
Conditions: Pulmonary Arterial Hypertension
At a glance
- Research payments reported, 2025
- $11,831
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 51
About the trial
- Sponsor
- United Therapeutics
- Tested
- Treprostinil Inhalation Powder (drug)
- Dates
- Started 2019-09-17; completion 2023-08-22
- Results posted
- Yes
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
From ClinicalTrials.gov, last updated 2024-11-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
United Therapeutics Corporation reported $11,831 in research payments for this study in 2025 (3 payments).
Products named: Tyvaso
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ricardo Restrepo-jaramillo, M.D. Pulmonology · Tampa, FL
- Trushil G. Shah, M.D. Critical Care Medicine · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The University of South Florida $10,331
- The University of Texas Southwestern Medical Center $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.